A patient developed transient intestinal ischemia while on semaglutide, representing a rare but serious GI adverse event requiring awareness as GLP-1 drug use expands.
Rare but seriousIntestinal ischemia is a rare semaglutide complication that clinicians should consider when evaluating severe abdominal pain in GLP-1 drug users
What the researchers found
Transient intestinal ischemia occurred in a semaglutide user, representing a rare but serious GI adverse event requiring clinical awareness.
Why it matters
Severe abdominal pain in semaglutide users should prompt consideration of intestinal ischemia as a rare differential diagnosis.
How the study worked
Single case report with clinical documentation of intestinal ischemia during semaglutide therapy.
What this study cannot tell us
Single case. Cannot establish incidence. Other contributing factors possible.
How to read the evidence
Single case report. Important for awareness despite low evidence level.
When this study was published
Published in 2025.
The bigger picture
As GLP-1 drug use scales to millions, rare adverse events like intestinal ischemia will be encountered more frequently.
Questions still open
- How common is GLP-1-associated intestinal ischemia?
- Does the mechanism involve motility changes, vascular effects, or both?
- Should vascular history be a relative contraindication for GLP-1 drugs?
Common questions
Can semaglutide affect blood flow to the intestines?
Should I worry about this on semaglutide?
Read the original research
Semaglutide-induced transient intestinal ischemia: A case report.
International journal of clinical pharmacology and therapeutics, 64(3), 154-158
Citation
Kalluru, Pavan Kumar Reddy; Cherukuri, Apoorva; Kuchi, Deekshitha; Topacio, Antonia. (2026). Semaglutide-induced transient intestinal ischemia: A case report.. International journal of clinical pharmacology and therapeutics, 64(3), 154-158. https://doi.org/10.5414/CP204861